New hope for liver cancer patients with shunts: Drug-Coated beads vs. standard treatment
NCT ID NCT07322848
First seen Jan 11, 2026 · Last updated Jun 21, 2026 · Updated 14 times
Summary
This Phase 3 trial tests whether drug-eluting beads (DEB-TACE) work better and are safer than standard chemoembolization (cTACE) for liver cancer patients who have had a TIPS procedure to manage complications of cirrhosis. The study will enroll 206 participants and compare survival, tumor response, and quality of life over 24 months. The goal is to find the best treatment option for this challenging patient group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiiated Hospital of Sun Yat-sen University
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Drug-eluting beads loaded with epirubicin or doxorubicin
What this could lead to
If successful, this could establish a safer and more effective standard treatment for liver cancer patients who have limited options after a TIPS procedure.
What could go wrong
This is a relatively small Phase 3 trial in a specific patient group, and the altered liver blood flow after TIPS may still cause toxicity or limit effectiveness. Results may not apply to all liver cancer patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.